Posts by Althian Clinical Research

Patient enrollment and retention challenges in clinical trials

Patient retention in clinical trials in key for its successful completion and strength of the results. According to United BioSource,...

Getting sick costs pricey

Most of us may have asked ourselves this question: Why does getting sick has to be so expensive? Getting sick...

Cancer and its new accomplice

For many years, many researches suspected that some bacteria could be involved in the development of many cancers. For example,...

New research in type 1 diabetes using PD-L1

Type 1 diabetes is an autoinmune condition in which the immune cells attack the islet cells in the pancreas that...

Zydus Cadila’s LipaglynTM (Saroglitazar Magnesium) receives regulatory approval in Mexico

Zydus Cadila is an innovative, global pharmaceutical company who is eager to create healthier communities all around the world. In...

Alternative options for renal cell carcinoma

The renal cell carcinoma (RCC) is the eight most common and aggressive cancer.  Unfortunately, there are poor treatments methods. Right...

Insights in non-alcoholic steatohepatitis (NASH)

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) which occurs when fat builds up on the...

What’s new in multiple sclerosis treatment research?

Multiple sclerosis (MS) is an inflammatory, neurodegenerative disease that affects the central nervous system by making it a potentially disabling...

New proposals for oncology treatment: nanomedicine

In recent years, novel therapies for cancer have been proposed. Nanomedicine is the new field that has a novel proposal:...

Eli Lilly’s Verzenio™ (Abemaciclib) receives FDA approval for certain advanced breast cancers

Last week the Food and Drug Administration (FDA) announced the approval of Eli Lilly’s breast cancer drug: Verzenio™ (Abemaciclib). This...

Visit Us On FacebookVisit Us On Linkedin